Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 2
2022 5
2023 6
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
Díaz-González Á, Hernández-Guerra M, Pérez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Díaz A, Gómez E, Morillas RM, Del Barrio M, Escudé L, Mateos B, Horta D, Gómez J, Conde I, Ferre-Aracil C, El Hajra I, Arencibía A, Zamora J, Fernández A, Salcedo M, Molina E, Soria A, Estévez P, López C, Álvarez-Navascúes C, García-Retortillo M, Crespo J, Londoño MC; ColHai Registry. Díaz-González Á, et al. Among authors: barreira diaz a. Hepatology. 2023 Apr 1;77(4):1095-1105. doi: 10.1097/HEP.0000000000000018. Epub 2023 Jan 3. Hepatology. 2023. PMID: 36626622 Free article.
Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry.
Riveiro-Barciela M, Barreira-Díaz A, Esteban P, Rota R, Álvarez-Navascúes C, Pérez-Medrano I, Mateos B, Gómez E, De-la-Cruz G, Ferre-Aracil C, Horta D, Díaz-González Á, Ampuero J, Díaz-Fontenla F, Salcedo M, Ruiz-Cobo JC, Londoño MC. Riveiro-Barciela M, et al. Among authors: barreira diaz a. Liver Int. 2024 Sep;44(9):2303-2314. doi: 10.1111/liv.15970. Epub 2024 May 29. Liver Int. 2024. PMID: 38809086
Toxicities from immunotherapy: From clinical trials to real-world clinical practice.
Riveiro-Barciela M, Trallero-Araguás E, Martínez-Valle F; Vall d’Hebrón Group for the study of Immunotherapy immune-related adverse events; Vall d’Hebrón Committee for management of Immunotherapy immune-related adverse events. Riveiro-Barciela M, et al. Med Clin (Barc). 2020 Dec 24;155(12):541-547. doi: 10.1016/j.medcli.2020.06.057. Epub 2020 Aug 28. Med Clin (Barc). 2020. PMID: 32868034 Review. English, Spanish.
LINK-B: study protocol of a retrospective and prospective project for identification and linkage to care of people living with hepatitis B in a large health area of Barcelona.
Barreira Díaz A, Rando A, Feliu-Prius A, Palom A, Rodríguez-Frías F, Vargas-Accarino E, Vico-Romero J, Palomo N, Riveiro-Barciela M, Esteban R, Buti M. Barreira Díaz A, et al. BMJ Open. 2022 Dec 23;12(12):e062680. doi: 10.1136/bmjopen-2022-062680. BMJ Open. 2022. PMID: 36564118 Free PMC article.
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M, Barreira-Díaz A, Callejo-Pérez A, Muñoz-Couselo E, Díaz-Mejía N, Díaz-González Á, Londoño MC, Salcedo MT, Buti M. Riveiro-Barciela M, et al. Among authors: barreira diaz a. Clin Gastroenterol Hepatol. 2023 Mar;21(3):732-740. doi: 10.1016/j.cgh.2022.03.050. Epub 2022 Apr 26. Clin Gastroenterol Hepatol. 2023. PMID: 35487453
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.
Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, Mínguez B, Ortiz-Velez C, Castells L, Esteban R, Buti M. Riveiro-Barciela M, et al. Among authors: barreira diaz a. Liver Int. 2020 Aug;40(8):1906-1916. doi: 10.1111/liv.14489. Epub 2020 Jun 3. Liver Int. 2020. PMID: 32329119
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.
Aceituno L, Bañares J, Ruiz-Ortega L, Callejo-Pérez A, Muñoz-Couselo E, Ortiz-Velez C, Díaz-Mejía N, Barreira-Díaz A, Carreras MJ, Farriols A, Buti M, Riveiro-Barciela M. Aceituno L, et al. Among authors: barreira diaz a. Front Med (Lausanne). 2022 Jul 15;9:916213. doi: 10.3389/fmed.2022.916213. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911389 Free PMC article.
18 results